ClinicalTrials.gg
RecruitingNCT06386185DRAPEUpdated Jun 18, 2025

Developing the Probability Algorithm for Pulmonary Hypertension Echocardiography

An observational study in Pulmonary Hypertension, sponsored by Royal United Hospitals Bath NHS Foundation Trust. Recruiting at 5 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-18.

Sponsored by Royal United Hospitals Bath NHS Foundation Trust · Observational

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
2,500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 117 studies in Hypertension, Pulmonary with a site in United Kingdom — 22 open to participants now, 27 under way, 3 of them phase 3. Hypertension, Pulmonary · United Kingdom.

Planned enrollment
Largest of 33
2,500 · median 200
Started
2024
with 4 others
Observational
33 of 117
12 open now
Primary completion
2026-12
later than 9 of 26 live
Registered
102nd of 117
by date
Lead sponsor
4 of 117
Royal United Hospitals Bath NHS Foundation Trust

Among the 117 studies in Hypertension, Pulmonary with a site in United Kingdom, this one has the largest planned enrollment of the 33 observational ones that give a count, is one of 5 that started in 2024, is one of 33 observational ones, reaches primary completion later than 9 of the 26 other live ones, and was the 102nd registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

22 of the 117 studies in Hypertension, Pulmonary with a site in United Kingdom are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 117 studies in Hypertension, Pulmonary with a site in United Kingdom, or all of them as a file.
02

Study summary

The goal of this observational study is to assess the efficacy that the addition of novel markers cardiac function, particularly of right ventricular (RV) function in echocardiography, and ECG have in detecting pulmonary hypertension.

The main questions it aims to answer are:

Can novel markers in ECG and echocardiography suggest the presence of PH? Can existing screening guidelines be improved with the addition of these markers?

Read the detailed description

Pulmonary Hypertension (PH) is a condition caused by high blood pressure in the blood vessels that carry blood to the lungs. It can cause severe breathlessness and failure of the right side of the heart. Sadly it is often fatal.

PH can be caused by a number of different conditions and life expectancy varies with the underlying cause, ranging from months to years. For some subtypes of PH, effective treatments exist which can significantly improve life expectancy and quality of life. Accurate tools for the assessment of PH are therefore essential, so that we can better understand and predict life expectancy and so that life-saving medications can be started earlier.

Once doctors suspect that somebody has PH, they refer them to a specialist PH centre for assessment and a procedure called right heart catheterisation (RHC), which will confirm the diagnosis. However, evidence for the suspicion of PH is frequently overlooked, leading to an average delay to diagnosis from onset of symptoms of two years. This late presentation negatively impacts survival for these patients and prevents them promptly starting the effective treatments which are available.

An electrocardiogram (ECG) is a recording of the heart's electrical signals, printed in waveforms. It is a painless, low-cost, and readily-available test used in PH assessment.

Echocardiography (echo) is a quick, safe and well-tolerated test often requested to investigate breathless patients and can provide useful information about the suspicion of PH. Echo has however been shown to lack accuracy in milder forms of the disease. It has been hypothesised that subtle markers of right ventricular function by echo, such as free wall strain (RVFWS) begin to deteriorate before the more established findings.

A large, cross-population study of ECG features and echo markers such as RVFWS both in isolation and in combination, in patients referred for PH assessment may help identify these markers, and improve detection of the disease.

03

Conditions studied

  • Pulmonary Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients aged 18+ referred for first time assessment of PH, who have undergone ECG, TTE, and RHC as part of their routine investigation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 18+ who have undergone TTE, and RHC as part of their clinical care

Exclusion criteria

Exclusion Criteria:

  • Patients \<18 years old
  • Known or suspected congenital heart disease
  • Patient has opted-out of allowing their data to be used for research and planning (via the national data opt-out choice in England, or equivalent data protection scheme in Scotland)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
2,500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Diagnostic Test

    Patients referred for initial PH investigations, who underwent ECG and echo screening prior to RHC.

    Diagnostic Test: Electrocardiogram · Diagnostic Test: Transthoracic echocardiogram · Diagnostic Test: Right heart catheter

Interventions

  • Diagnostic testElectrocardiogram

    Non-invasive multi-vector voltage/time graph visualising the electrical conduction of the heart

    Also known as: ECG

  • Diagnostic testTransthoracic echocardiogram

    Non-invasive 2 \& 3 dimensional imaging of the heart using ultrasound

    Also known as: Echo, TTE

  • Diagnostic testRight heart catheter

    Minimally invasive cardiac chamber pressure measurement using balloon catheterisation

    Also known as: RHC

06

What researchers measure

Primary outcomes

  1. Distinguish between patients with and without pulmonary hypertension

    Assessment of novel echo markers of cardiac function in improving the current assessment framework's ability to correctly identify or exclude the presence of pulmonary hypertension based on a mean pulmonary artery pressure greater than 20mmHg as measured by right heart catheter. There is no reporting scale, rather markers will be used to assess a binary yes/no with regards to the presence of pulmonary hypertension

    Time frame: 2 years

  2. Distinguish between patients with pre-capillary hypertension and post-capillary hypertension

    Assessment of novel echo markers of cardiac function in determining the subtype of pulmonary hypertension (i.e. pulmonary hypertension secondary to left heart disease, or pulmonary hypertension emanating from pulmonary abnormality) based on a mean pulmonary artery pressure greater than 20mmHg, pulmonary vascular resistance, or pulmonary capillary wedge pressure as measured by right heart catheter. There is no reporting scale, rather markers will be used to assess a binary yes/no with regards to the presence of pulmonary hypertension

    Time frame: 2 years

Secondary outcomes

  1. Assess the impact of the severity of pulmonary hypertension

    Existing research has demonstrated that current assessment guidelines are less accurate in milder forms of pulmonary hypertension. We aim to assess any improvements to the overall efficacy that novel markers of cardiac function may have, particularly in those with low echocardiographic probability as determined by European Society of Cardiology echocardiographic guidelines for the assessment of pulmonary hypertension. There is no reporting scale, rather markers will be used to assess a binary yes/no with regards to the presence of pulmonary hypertension

    Time frame: 2 years

  2. Assess the impact of additional electrocardiogram markers on existing pulmonary hypertension probability stratification

    Assessment of novel electrocardiogram markers in improving pulmonary hypertension assessment guidelines, particularly in those with low echocardiographic probability as determined by European Society of Cardiology echocardiographic guidelines for the assessment of pulmonary hypertension. There is no reporting scale, rather markers will be used to assess a binary yes/no with regards to the presence of pulmonary hypertension

    Time frame: 2 years

07

Study locations

1 of 5 sites recruiting
  • Royal United Hospital NHS Foundation Trust
    Bath, Banes BA1 3NG, United Kingdom
    Recruiting
    • Christopher JB Wild, BSc (Hons) · Contactchris.wild1@nhs.net · 07891662866
    • Jane Carter · Contactjane.carter14@nhs.net · 01225 824295
    • Daniel X Augustine, MBBS · Principal investigator
    • Christopher JB Wild, BSc(Hons) · Sub investigator
    • Jay Suntharalingham · Sub investigator
    • Robert Mackenzie-Ross · Sub investigator
  • Golden Jubilee Hospital
    Glasgow, Lanarkshire G81 4DY, United Kingdom
    Not yet recruiting
  • Sheffield Teaching Hospitals NHS Foundation Trust
    Sheffield, South Yorkshire S10 2JF, United Kingdom
    Not yet recruiting
  • Royal Papworth Hospital
    Cambridge, CB2 0AY, United Kingdom
    Not yet recruiting
    • Madalina Garbi · Contactmadalina.garbi@nhs.net
    • Madalina Garbi · Principal investigator
    • Joana Pepke-Zaba · Sub investigator
  • Royal Free NHS Foundation Trust
    London, NW3 2QG, United Kingdom
    Not yet recruiting
    • Gerry Coghlan · Contactgerry.coghlan@nhs.net
    • Gerry Coghlan · Principal investigator
    • Daniel Knight · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2024
First posted
Apr 26, 2024
StartActual
Sep 6, 2024
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Jun 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06386185
Lead sponsor
Royal United Hospitals Bath NHS Foundation Trust
Collaborators
Sheffield Teaching Hospitals NHS Foundation Trust, Royal Free Hospital NHS Foundation Trust, Golden Jubilee National Hospital, Papworth Hospital NHS Foundation Trust, University of Bath
Responsible party
Sponsor
First posted
Apr 26, 2024
Start date
Sep 6, 2024
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Jun 18, 2025

Study contacts

Christopher Wild
Contact
chris.wild1@nhs.net
+4407891662866
Jane Carter
Contact
jane.carter14@nhs.net
+4401225821905
Daniel X Augustine
principal investigator · Royal United Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion